<DOC>
	<DOC>NCT00168090</DOC>
	<brief_summary>The purpose of this study is to test the safety and effectiveness of Humate-P® to prevent bleeding in patients with von Willebrand Disease who are undergoing surgery.</brief_summary>
	<brief_title>Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Blood Platelet Disorders</mesh_term>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Key Subjects of any age Clinical and laboratory diagnosis of vWD that can be expected to show no hemostatic response to DDAVP Require substitution with vWF/FVIII complex due to a surgery Key Known significant hemostatic disorder other than vWD Acquired vWD Known antibodies to FVIII or vWF Known platelet type vWD Emergency surgery or any surgery with a degree of urgency not permitting completion of a pharmacokinetic assessment required by the study protocol History of allergic reaction to HumateP® Treatment with any other investigational drug in the last four weeks before the entry into the study (with exception of trials concerning antiHIV agents) Progressive fatal disease/life expectancy of less than 6 months Treatment with DDAVP, cryoprecipitate, whole blood, plasma and plasma derivatives containing substantial quantities of FVIII and/or vWF within 5 days of the presurgical pharmacokinetic assessment Pediatric patients of insufficient body weight to permit PK sampling Woman in the first 20 weeks of pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>von Willebrand Factor</keyword>
	<keyword>Blood Coagulation Disorders</keyword>
	<keyword>Factor VIII</keyword>
</DOC>